681 results match your criteria CNS Melanoma


Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature.

Front Oncol 2019 26;9:168. Epub 2019 Mar 26.

Department of Radiation Oncology, Taussig Cancer Center Institute, Cleveland Clinic, Cleveland, OH, United States.

Melanoma brain metastasis with ependymal spread/metastases is uncommon. These cases are frequently classified together with leptomeningeal disease. However, the commonalities and differences in the underlying pathophysiology and clinical outcomes between these two types of spread are not clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443873PMC
March 2019
2 Reads

Primary intracranial malignant melanoma: proposed treatment protocol and overall survival in a single-institution series of 15 cases combined with 100 cases from the literature.

J Neurosurg 2019 Mar 1:1-12. Epub 2019 Mar 1.

OBJECTIVEThe overall survival and pertinent adverse factors for primary intracranial malignant melanoma (PIMM) have not been previously determined. This aim of this study was to determine the rates of progression-free survival (PFS) and overall survival (OS) and identify the adverse factors for PIMM.METHODSThis study included 15 cases from the authors' own series and 100 cases with detailed clinical data that were obtained from the literature from 1914 to 2018 using the Ovid Medline, EMBASE, PubMed, Cochrane, and EBSCO databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.11.JNS181872DOI Listing
March 2019
1 Read

Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.

J Neuroinflammation 2019 Feb 26;16(1):49. Epub 2019 Feb 26.

Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.

Background: Quinoline-3-carboxamides, such as laquinimod, ameliorate CNS autoimmunity in patients and reduce tumor cell metastasis experimentally. Previous studies have focused on the immunomodulatory effect of laquinimod on myeloid cells. The data contained herein suggest that quinoline-3-carboxamides improve the immunomodulatory and anti-tumor effects of NK cells by upregulating the adhesion molecule DNAX accessory molecule-1 (DNAM-1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12974-019-1437-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390632PMC
February 2019
3 Reads

Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.

Lancet Oncol 2019 Apr 21;20(4):531-545. Epub 2019 Feb 21.

Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. Electronic address:

Background: Few studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer.

Methods: The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of cancer diagnosed when aged 15-39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30903-3DOI Listing
April 2019
1 Read

Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation.

Front Neurol 2019 7;10:79. Epub 2019 Feb 7.

Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.

Melanocytic nevi present at birth, or within the first few months of life, are defined as congenital melanocytic nevi (CMN). Neurocutaneous melanosis (NCM) is a rare disorder, represents pigment cell tumors of the leptomeninges, and occurs in association with large or multiple CMN. NCM carries an extremely poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374324PMC
February 2019
3 Reads

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Pigment Cell Melanoma Res 2019 05 19;32(3):458-469. Epub 2019 Feb 19.

Moffitt Cancer Center, Tampa, Florida.

In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System (CNS) Metastases in Tampa, Florida. In this white paper, we outline the current status of basic science, translational, and clinical research into melanoma brain metastasis development and therapeutic management. We further outline the important challenges that remain for the field and the critical barriers that need to be overcome for continued progress to be made in this clinically difficult area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12771DOI Listing
May 2019
2 Reads

Thioredoxin, glutathione and related molecules in tumors of the nervous system.

Curr Med Chem 2019 Jan 31. Epub 2019 Jan 31.

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa. Portugal.

Background: Central Nervous System (CNS) tumors have a poor survival prognosis due to their invasive and heterogeneous nature, in addition to the resistance to multiple treatments.

Objective: In this paper, the main aspects of brain tumor biology and pathogenesis are reviewed both for primary tumors of the brain, (i.e. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/169547/article
Publisher Site
http://dx.doi.org/10.2174/0929867326666190201113004DOI Listing
January 2019
5 Reads

Primary leptomeningeal melanocytic tumors of the spine: report of two cases and review of the literature.

World Neurosurg 2019 Jan 17. Epub 2019 Jan 17.

Department of Neurosurgery, University Medicine Greifswald. Electronic address:

Primary leptomeningeal melanocytic tumors of the central nervous system are rare and especially in the spine less frequent compared to other entities. There is no consensus regarding the best care of these tumors. We report two cases of primary leptomeningeal melanocytic tumors, one PLM (Primary Leptomeningeal Melanoma) and one PLMC (Primary Leptomeningeal Melanocytoma) of the upper cervical spine and emphasize different surgical findings and clinical courses of these patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193009
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.01.015DOI Listing
January 2019
6 Reads

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

Immunotherapy 2019 Mar 4;11(4):297-309. Epub 2019 Jan 4.

Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.

Aim: Melanoma brain metastases (MBM) are associated with a dismal prognosis. Few clinical trials evaluated the impact of immunotherapy (IT) and targeted therapy (TT) alone or in combination with surgery and radiotherapy in this population.

Patients & Methods: Retrospective analysis of data from 163 patients diagnosed with MBM between January 2014 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0149DOI Listing
March 2019
4 Reads

An early feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma: first cohort in US.

CNS Oncol 2019 03 14;8(1):CNS30. Epub 2018 Dec 14.

Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.

Aim: Evaluation of the Nativis Voyager device in patients with recurrent glioblastoma (rGBM).

Materials & Methods: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE) that uses a magnetic field to penetrate tissues to alter specific biologic functions within cells. Patients with rGBM were treated with Voyager alone (V) or Voyager in combination with standard of care (V + SoC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2018-0013DOI Listing

Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis.

J Oncol Pract 2019 Jan 5;15(1):e20-e29. Epub 2018 Dec 5.

2 University of California, Davis, Sacramento, CA.

Purpose:: Reducing acute care use is an important strategy for improving value in cancer care. However, little information is available to describe and compare population-level hospital use across cancer types. Our aim was to estimate unplanned hospitalization rates and to describe the reasons for hospitalization in a population-based cohort recently diagnosed with cancer. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00254
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00254DOI Listing
January 2019
17 Reads

Differentiation between glioblastomas and brain metastases and regarding their primary site of malignancy using dynamic susceptibility contrast MRI at 3T.

J Neuroradiol 2018 Oct 30. Epub 2018 Oct 30.

Institution of Clinical Sciences, Lund University, Lund, Sweden; Department of Radiology, University of Michigan, Ann Arbor, US.

Background: Differentiation between glioblastoma and brain metastasis may be challenging in conventional contrast-enhanced MRI.

Purpose: To investigate if perfusion-weighted MRI is able to differentiate glioblastoma from metastasis and, as a second aim was to see if it was possible in the latter group, to predict the primary site of neoplasm.

Material And Methods: Hundred and fourteen patients with newly discovered tumor lesion (76 metastases and 38 glioblastomas) underwent conventional contrast-enhanced MRI including dynamic susceptibility contrast perfusion sequence. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01509861183012
Publisher Site
http://dx.doi.org/10.1016/j.neurad.2018.09.006DOI Listing
October 2018
7 Reads

Prevention of Brain Metastases.

Authors:
Joseph A Bovi

Front Neurol 2018 28;9:758. Epub 2018 Sep 28.

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.

The incidence of brain metastases is projected to rise because survival rates of lung cancer, breast cancer, and melanoma continue to improve (1). The brain is being identified as a sanctuary site for harboring metastases despite excellent control of extracranial disease. This is thought to occur because the drug therapies that control extracranial disease have limited central nervous system (CNS) penetration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.00758DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172309PMC
September 2018

Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.

Front Oncol 2018 27;8:414. Epub 2018 Sep 27.

Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.

While the CNS has long been viewed as an immune-privileged environment, a paradigm shift in neuro-immunology has elevated the role of systemic immunotherapy for the treatment of metastatic disease. Increasing knowledge regarding the presence of a CNS lymphatic system and the physical and biochemical alteration of the blood brain barrier (BBB) by the tumor microenvironment suggests immune cell trafficking in and out of the CNS is possible. Emerging clinical data suggest immune checkpoint inhibitors (ICIs) can stimulate T cells peripherally to in turn have anti-tumor effects in the CNS. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00414/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171475PMC
September 2018
19 Reads

Costs associated with adverse events for systemic therapies in metastatic melanoma.

J Comp Eff Res 2018 Sep 7;7(9):867-879. Epub 2018 Sep 7.

Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Corporation, Princeton Pike, NJ 08648, USA.

Aim: To determine the costs of adverse events (AEs) associated with current metastatic melanoma (MM) therapies.

Materials & Methods: Two retrospective cohort studies were independently conducted using the PharMetrics and MarketScan databases. Included patients were aged ≥18 years, and had ≥1 MM diagnosis and ≥1 claim for systemic therapy from 2004 to 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2018-0022DOI Listing
September 2018
3 Reads

Neurosarcoidosis following Immune Checkpoint Inhibition.

Case Rep Oncol 2018 May-Aug;11(2):521-526. Epub 2018 Jul 27.

Department of Neurology, Duke University, Durham, North Carolina, USA.

Recently, immune checkpoint inhibitors have revolutionized cancer care by enhancing anti-tumor immunity. However, by virtue of stimulating the immune system, they can lead to immune-related adverse events (irAEs). Neurologic irAEs are uncommon but are becoming increasingly recognized and can be quite serious or even fatal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120397PMC
July 2018
5 Reads

Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus.

J Neuroinflammation 2018 Aug 22;15(1):236. Epub 2018 Aug 22.

Clinic of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus-1, Building A01, 48149, Münster, Germany.

Background: Very late antigen 4 (VLA-4; integrin α4β1) is critical for transmigration of T helper (T) 1 cells into the central nervous system (CNS) under inflammatory conditions such as multiple sclerosis (MS). We have previously shown that VLA-4 and melanoma cell adhesion molecule (MCAM) are important for trans-endothelial migration of human T17 cells in vitro and here investigate their contribution to pathogenic CNS inflammation.

Methods: Antibody blockade of VLA-4 and MCAM is assessed in murine models of CNS inflammation in conjunction with conditional ablation of α4-integrin expression in T cells. Read More

View Article

Download full-text PDF

Source
https://jneuroinflammation.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s12974-018-1276-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106934PMC
August 2018
9 Reads

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.

Dermatology 2018 15;234(3-4):92-98. Epub 2018 Aug 15.

Background: Combined treatment with BRAF-V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with BRAF-mutated melanoma. Pattern of disease progression and outcomes in patients have not been fully characterized.

Methods: We conducted a single-center, retrospective, descriptive analysis of a cohort of 52 patients treated with BRAF-V600 + MEK inhibitors for advanced melanoma over a 12-month period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490891DOI Listing
December 2018
5 Reads

Dabrafenib-trametinib combination in 'field-practice': an Italian experience.

Future Oncol 2018 Aug 7;14(20):2045-2052. Epub 2018 Aug 7.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

Aim: This observational study investigates the effectiveness and safety of dabrafenib/trametinib combination in patients with metastatic melanoma.

Patients & Methods: Seventy-six patients treated with dabrafenib/trametinib (150 mg twice daily/2 mg once daily) were included.

Results: Median progression-free survival was 9 months (95% CI: 7-11) and median overall survival was 14 months (11-16); disease control rate was 72%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0714DOI Listing
August 2018
3 Reads

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.

J Immunother Cancer 2018 Jul 31;6(1):77. Epub 2018 Jul 31.

Division of Medical Oncology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC, 27701, USA.

Background: Immune checkpoint inhibitors have transformed the treatment landscape for many cancers, including metastatic melanoma, but have also opened the door for a diverse variety of immune-related adverse effects.

Case Presentation: We describe the first reported case of presumed neurosarcoidosis as an immune-related adverse effect that developed nearly a year after discontinuation of treatment with combination ipilimumab and nivolumab for recurrent metastatic melanoma. The patient was noted to develop clinical signs consistent with systemic sarcoidosis shortly after the initiation of treatment and underwent a biopsy of hilar lymphadenopathy that confirmed sarcoidosis and after which immunotherapy was discontinued. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0390-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069826PMC
July 2018
6 Reads

Myelopathy from Intradural Extramedullary Metastasis as an Initial Presentation of Metastatic Melanoma.

Cureus 2018 May 22;10(5):e2668. Epub 2018 May 22.

Neurosurgery, Maimonides Medical Center.

The incidence of metastatic melanoma (MM) has been steadily rising, and it is the third most common metastatic lesion to the central nervous system (CNS). Spinal intradural extramedullary (IDEM) MM is rare, and it is associated with coexisting or antecedent brain metastasis. Metastatic disease to the CNS is a complication of advanced disease, and it generally occurs months to years after initial diagnosis and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.2668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054369PMC
May 2018
3 Reads

New developments in brain metastases.

Ther Adv Neurol Disord 2018 28;11:1756286418785502. Epub 2018 Jun 28.

Department of Medicine I and Comprehensive Cancer Center CNS Unit (CCC-CNS), Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Patients with brain metastases (BM) are a population of high clinical need for new therapeutic approaches due to, as yet, very impaired survival prognosis. However, only few clinical trials have specifically addressed this prognostically highly heterogeneous patient population. New developments in the treatment of BM patients aim to reduce the side effects of local therapies, for example, by redefining the indications for stereotactic radiosurgery and whole-brain radiotherapy (WBRT) or introducing new applications like hippocampal sparing WBRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286418785502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048670PMC
June 2018
43 Reads

Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.

Bioorg Med Chem 2018 08 9;26(14):4209-4224. Epub 2018 Jul 9.

School of Chemistry, Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork, Ireland. Electronic address:

Synthesis and biological evaluation of a series of novel indole derivatives as anticancer agents is described. A bisindolylmaleimide template has been derived as a versatile pharmacophore with which to pursue chemical diversification. Starting from maleimide, the introduction of an oxygen to the headgroup (hydroxymaleimide) was initially investigated and the bioactivity assessed by screening of kinase inhibitory activity, identifying substituent derived selectivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2018.07.012DOI Listing

BRAF mutation leading to central nervous system rosai-dorfman disease.

Ann Neurol 2018 Jul 16;84(1):147-152. Epub 2018 Aug 16.

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.

Rosai-Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, in central nervous system (CNS)-restricted form. RDD is characterized histologically as a non-Langerhans cell histiocytosis composed of atypical CD68 /S-100 /CD1a macrophages demonstrating prominent emperipolesis and effacement of the surrounding tissue. Previously thought to represent a reactive process, recent studies have raised the possibility that RDD and other histiocytic lesions, including Erdheim-Chester and Langerhans cell histiocytosis, are clonal processes linked to somatic mutations in the mitogen-activated protein (MAP) kinase pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25281DOI Listing
July 2018
5 Reads

Emerging findings into molecular mechanism of brain metastasis.

Cancer Med 2018 Aug 10;7(8):3820-3833. Epub 2018 Jul 10.

Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.

Brain metastasis is an important cause of morbidity and mortality in cancer patients. Hence, the need to develop improved therapies to prevent and treat metastasis to the brain is becoming urgent. Recent studies in this area are bringing about some advanced progress on brain metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089171PMC
August 2018
3 Reads

The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.

Int J Cancer 2019 02 1;144(4):802-817. Epub 2018 Nov 1.

Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Melanoma has the highest propensity to metastasize to the brain compared to other cancers, as brain metastases are found frequently high in patients who have prolonged survival with visceral metastasis. Once disseminated in the brain, melanoma cells communicate with brain resident cells that include astrocytes and microglia. Microglia cells are the resident macrophages of the brain and are the main immunological cells in the CNS involved in neuroinflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31745DOI Listing
February 2019
8 Reads

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment.

Radiol Case Rep 2018 Aug 3;13(4):882-885. Epub 2018 Jul 3.

Department of Radiology, Oregon Health Science University, Portland, OR, USA.

Immune checkpoint inhibitors are increasingly used in treatment of metastatic renal cell carcinoma, melanoma, and nonsmall cell lung cancer, as well as in clinical trials for novel targets. We present a pediatric patient with metastatic alveolar soft part sarcoma who was treated with MPDL3280 (Atezolizumab), a monoclonal anti-programmed death ligand-1 antibody. Imaging results for the patient suggested disease progression of multiple brain metastases with stable systemic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radcr.2018.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037874PMC
August 2018
7 Reads

The role of next-generation sequencing in the differential diagnosis of composite neoplasms.

Hum Pathol 2018 Nov 26;81:78-88. Epub 2018 Jun 26.

Department of Pathology, University of Illinois, Chicago, IL, USA. Electronic address:

Composite neoplasms (CNs) are rare and diagnostically challenging lesions that require differentiating between mixed clonal tumors with divergent phenotypes (MT), collision of 2 independent tumors adjacent to each other (CT), and tumor-to-tumor metastasis (TTM). To that end, pathologists have traditionally used immunohistochemistry and limited molecular studies, such as Sanger sequencing. Herein we evaluate the potential application of NGS in the differential diagnosis of these rare neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.06.022DOI Listing
November 2018
4 Reads

Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.

J Neurooncol 2018 Oct 16;140(1):55-62. Epub 2018 Jun 16.

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.

Introduction: Brain metastases are common in metastatic melanoma and radiosurgery is often utilized for local control. Immune checkpoint inhibitors (CPIs) play a central role in contemporary melanoma management; however, there is limited data exploring outcomes and potential toxicities for patients treated with CPIs and radiosurgery.

Methods: We retrospectively identified all consecutive cases of newly diagnosed melanoma brain metastases (MBM) treated with Gamma Knife radiosurgery at a single institution between 2012 and 2017, and included only patients that initiated CPIs within 8 weeks before or after radiosurgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2930-5DOI Listing
October 2018
7 Reads

Conditional relative survival among long-term survivors of adolescent and young adult cancers.

Cancer 2018 Jul 9;124(14):3037-3043. Epub 2018 May 9.

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care.

Methods: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033635PMC
July 2018
2 Reads

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Oncologist 2018 Sep 27;23(9):1063-1075. Epub 2018 Apr 27.

Medical Oncology, Austin Hospital, Heidelberg, Melbourne, Australia.

Primary and metastatic tumors of the central nervous system present a difficult clinical challenge, and they are a common cause of disease progression and death. For most patients, treatment consists primarily of surgery and/or radiotherapy. In recent years, systemic therapies have become available or are under investigation for patients whose tumors are driven by specific genetic alterations, and some of these targeted treatments have been associated with dramatic improvements in extracranial and intracranial disease control and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192601PMC
September 2018
13 Reads

A Comparative Review of Demographics, Incidence, and Epidemiology of Histologically Confirmed Intracranial Tumors in Brazil and Bulgaria.

Cureus 2018 Feb 19;10(2):e2203. Epub 2018 Feb 19.

Laboratory of Epidemiology and Data Analysis, Faculdadede Medicina Do Abc, Santo André, São Paulo, Brazil.

Intracranial tumors (ICTs) attract numerous scientific teams and tremendous financial resources worldwide. These lesions of the central nervous system (CNS) can be both benign and malignant in biological behavior as well as local or metastatic in origin. We compared data from two studies on primary and metastatic ICTs from Brazil and Bulgaria, based on histopathologically confirmed ICTs from tertiary health centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.2203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908715PMC
February 2018
6 Reads

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.

J Immunother Cancer 2018 Apr 6;6(1):25. Epub 2018 Apr 6.

NewYork-Prebsyterian/Columbia, Hematology/Oncology, 161 Fort Washington Ave, New York, NY, 10032, USA.

Background: Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing on first-line immunotherapy remains challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0338-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887256PMC
April 2018
10 Reads

Metastatic primary anorectal melanoma developing in a patient treated for multicentric glioblastoma multiforme: two rare malignancies presenting in synchronicity.

BMJ Case Rep 2018 Mar 21;2018. Epub 2018 Mar 21.

General Surgery, Batra Hospital and Medical Research Centre, New Delhi, Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-223450DOI Listing
March 2018
4 Reads

Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future Trials.

Oncology (Williston Park) 2018 03 15;32(3):e33-e37. Epub 2018 Mar 15.

The brain has long been considered an immunologically privileged site, and the role of immunotherapy in treating intracranial disease has only recently been revived-with preclinical evidence showing that the systemic immune system responds to immunotherapy for intracranial disease, and with clinical evidence demonstrating improved locoregional control and survival compared with historical outcomes when immune-directed therapies are combined with radiation. Pharmaceutical industry-supported multi-institutional drug efficacy studies routinely exclude patients with brain metastases, so current evidence for treatment of brain metastases using stereotactic radiosurgery combined with immunotherapy comes from single-institution studies. Many studies of combinations of immune checkpoint blockade (with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 antibodies) with stereotactic radiosurgery have demonstrated promising improvements in intracranial control and survival. Read More

View Article

Download full-text PDF

Source
March 2018
9 Reads

Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment.

Oncology (Williston Park) 2018 02 15;32(2):e28-e32. Epub 2018 Feb 15.

The role of systemic therapy in the treatment of intracranial metastases has traditionally been limited by the blood-brain barrier, and radiation therapy-either with whole-brain treatment or stereotactic radiosurgery-has remained a primary treatment modality. Recent evidence has demonstrated that antigens released in the brain can inform the systemic immune system, and systemic antibodies can traverse into the brain. This has led to a renewed interest in investigating novel immunotherapy agents to treat both systemic and intracranial disease. Read More

View Article

Download full-text PDF

Source
February 2018
4 Reads

Targeted therapy of brain metastases: latest evidence and clinical implications.

Ther Adv Med Oncol 2017 Dec 15;9(12):781-796. Epub 2017 Nov 15.

Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, CA-51, Cleveland, OH 44195, USA.

Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017736252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808839PMC
December 2017
8 Reads

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Drug Metab Dispos 2018 05 2;46(5):658-666. Epub 2018 Feb 2.

Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (G.G., M.K., N.C.-R., J.K.L., W.F.E.); Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); and Strategia Therapeutics Inc., Spring, Texas (L.P., L.D.)

Clinically meaningful efficacy in the treatment of brain tumors, including melanoma brain metastases (MBM), requires selection of a potent inhibitor against a suitable target, and adequate drug distribution to target sites in the brain. Deregulated constitutive signaling of mitogen-activated protein kinase (MAPK) pathway has been frequently observed in melanoma, and mitogen-activated protein/extracellular signal-regulated kinase (MEK) has been identified to be an important target. E6201 is a potent synthetic small-molecule MEK inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.117.079194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896365PMC
May 2018
8 Reads

Lab-Attenuated Rabies Virus Causes Abortive Infection and Induces Cytokine Expression in Astrocytes by Activating Mitochondrial Antiviral-Signaling Protein Signaling Pathway.

Front Immunol 2017 19;8:2011. Epub 2018 Jan 19.

State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.

Rabies is an ancient disease but remains endemic in most parts of the world and causes approximately 59,000 deaths annually. The mechanism through which the causative agent, rabies virus (RABV), evades the host immune response and infects the host central nervous system (CNS) has not been completely elucidated thus far. Our previous studies have shown that lab-attenuated, but not wild-type (wt), RABV activates the innate immune response in the mouse and dog models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2017.02011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785723PMC
January 2018
20 Reads

The biology and therapeutic management of melanoma brain metastases.

Biochem Pharmacol 2018 07 24;153:35-45. Epub 2017 Dec 24.

The Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, United States. Electronic address:

The recent years have seen significant progress in the development of systemic therapies to treat patients with advanced melanoma. Use of these new treatment modalities, which include immune checkpoint inhibitors and small molecule BRAF inhibitors, lead to increased overall survival and better outcomes. Although revolutionary, these therapies are often less effective against melanoma brain metastases, and frequently the CNS is the major site of treatment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2017.12.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959746PMC
July 2018
7 Reads

Management of intracranial melanomas in the era of precision medicine.

Oncotarget 2017 Oct 13;8(51):89326-89347. Epub 2017 Jul 13.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Melanoma is the most lethal of skin cancers, in part because of its proclivity for rapid and distant metastasis. It is also potentially the most neurotropic cancer in terms of probability of CNS metastasis from the primary lesion. Despite surgical resection and radiotherapy, prognosis remains guarded for patients with brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687693PMC
October 2017
11 Reads

Employing patient-reported outcome (PRO) measures to support newly diagnosed patients with melanoma: Feasibility and acceptability of a holistic needs assessment intervention.

Eur J Oncol Nurs 2017 Dec 6;31:59-68. Epub 2017 Nov 6.

Department of Computer and Information Sciences, University of Strathclyde, Glasgow, UK. Electronic address:

Purpose: Living with a melanoma diagnosis can be challenging. We aimed to assess the feasibility, acceptability, and perceived value of a nurse-led intervention that utilised patient-reported outcome (PRO) measures to identify and address the supportive care needs of newly diagnosed patients with Stage I/II melanoma over the first 4 months post-diagnosis.

Methods: We conducted an exploratory, repeated-measures, single-arm, feasibility trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejon.2017.10.002DOI Listing
December 2017
6 Reads

Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma.

Clin Neurol Neurosurg 2018 01 20;164:32-38. Epub 2017 Nov 20.

Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address:

Objectives: Primary intracranial malignant melanoma (PIMM) is extremely rare central nervous system (CNS) tumor and known for only composed 0.07% of the CNS tumors. PIMM composed only 1% of malignant melanoma and accordingly their clinical behavior and prognosis are not well documented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2017.11.012DOI Listing
January 2018
6 Reads

Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies.

Stereotact Funct Neurosurg 2017 4;95(6):363-368. Epub 2017 Nov 4.

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

Background: Gamma knife radiosurgery (GKR) can be used for precise targeting of malignant lesions of the CNS when brachytherapy is not an appropriate option.

Objectives: This study reports treatment technique, efficacy, and radiation-induced adverse effects in patients with primary and metastatic ocular lesions treated with Leksell GKR.

Methods: A retrospective, single-institution review was conducted of 28 patients with primary or metastatic ocular disease, treated from 2000 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000478271DOI Listing
December 2018
15 Reads

Chemical meningitis related to intra-CSF liposomal cytarabine.

CNS Oncol 2017 10 23;6(4):261-267. Epub 2017 Oct 23.

Lille University, F-59000 Lille, France.

Therapeutic options of leptomeningeal metastases include intra-cerebrospinal fluid (CSF) chemotherapy. Among intra-CSF agents, liposomal cytarabine has advantages but can induce specific toxicities. A BRAF-V600E-mutated melanoma leptomeningeal metastases patient, treated by dabrafenib and liposomal cytarabine, presented after the first injection of liposomal cytarabine with hyperthermia and headaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2016-0046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004879PMC
October 2017
8 Reads

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Cancer Med 2017 Nov 10;6(11):2576-2585. Epub 2017 Oct 10.

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan.

The incidence of CNS progression in patients with high-risk regional melanoma (stages IIIAN2a-IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival. All patients were surgically staged. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673911PMC
November 2017
18 Reads

Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.

Front Oncol 2017 25;7:230. Epub 2017 Sep 25.

Departments of Neurology and Radiation Oncology, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States.

In the current era of molecularly targeted therapies and precision medicine, choice of cancer treatment has been increasingly tailored according to the molecular or genomic characterization of the cancer the individual has. Previously, the clinical observation of inadequate control of brain metastases was widely attributed to a lack of central nervous system (CNS) penetration of the anticancer drugs. However, more recent data have suggested that there are genetic explanations for such observations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622141PMC
September 2017
5 Reads

Leiomyosarcoma of the infratemporal fossa with perineurial spread along the right mandibular nerve: a case report.

CNS Oncol 2017 10 9;6(4):281-285. Epub 2017 Oct 9.

Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA.

Leiomyosarcomas are malignant tumors displaying strong smooth muscle differentiation. They can often develop within the GI tract and myometrium, but are particularly rare in the head and neck. Perineurial spread of head and neck cancer is observed in patients with neoplasms of the skin (squamous cell carcinoma, melanoma) or skin appendages (adenoid cystic carcinoma). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2017-0004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004886PMC
October 2017
22 Reads

Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature.

Neurosurg Rev 2018 Jan 6;41(1):333-339. Epub 2017 Oct 6.

Department of Dermatology, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan.

Leptomeningeal melanomatosis is an extremely rare variant of primary central nervous system (CNS) melanoma and has a poor prognosis and no standard treatment. Primary CNS melanoma is derived from the melanocytes of the leptomeninges. Here, we describe a case of a 37-year-old male who visited our hospital due to worsening headaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10143-017-0914-0DOI Listing
January 2018
15 Reads

Mechanisms of phosphenes in irradiated patients.

Oncotarget 2017 Sep 28;8(38):64579-64590. Epub 2017 Jun 28.

Proton Therapy Center, Université Nice Sophia Antipolis, 06200 Nice, France.

Anomalous visual perceptions have been reported in various diseases of the retina and visual pathways or can be experienced under specific conditions in healthy individuals. Phosphenes are perceptions of light in the absence of ambient light, occurring independently of the physiological and classical photonic stimulation of the retina. They are a frequent symptom in patients irradiated in the region of the central nervous system (CNS), head and neck and the eyes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610027PMC
September 2017
10 Reads